```html

Kawasaki Disease (Classic) – Comprehensive Medical Guide

Overview

Kawasaki disease (KD), also called mucocutaneous lymph node syndrome, is an acute, self‑limited vasculitis that predominantly affects medium‑sized arteries, especially the coronary arteries. The classic form—sometimes simply referred to as “Kawasaki disease”—is characterized by a specific set of clinical criteria that appear in a predictable sequence over 1–2 weeks.

• Age group: >90 % of cases occur in children <5 years old; the peak incidence is 18–24 months.
• Sex: Boys are about 1.5–1.8 times more likely to develop the disease.
• Geography & ethnicity: Highest incidence in East Asian populations (Japan ≈ 264/100 000 children <5 years; Korea ≈ 112/100 000). In North America, the overall incidence is ≈ 20–25/100 000 children <5 years, with higher rates among Asian‑American children.
• Seasonality: Peaks in winter–early spring in temperate climates, suggesting an infectious trigger.

Although the exact cause remains unknown, prompt diagnosis and treatment dramatically reduce the risk of serious cardiac complications.

Symptoms

Classic Kawasaki disease is diagnosed when fever lasts ≥5 days plus at least four of the five principal clinical features. The symptom list below follows the American Heart Association (AHA) criteria.

1. Fever

• High, persistent fever (≥38.5 °C/101.3 °F) that does not respond to typical antipyretics.
• Usually the first sign, lasting 5–11 days before other features emerge.

2. Conjunctival Injection

• Bilaterally red eyes without exudate or purulent discharge.
• Often described as “bloodshot” but painless.

3. Oral Mucosal Changes

• Bright red “strawberry” tongue (prominent papillae), cracked lips, erythema of the oropharynx.
• Changes appear early and may persist for weeks.

4. Extremity Changes

• Acute phase: swelling, erythema, and warmth of the hands and feet.
• Subacute phase (2–3 weeks): desquamation (peeling) of skin on fingertips and toes, often in a “shedding” pattern.
• Later: periungual edema and nail changes (e.g., transverse ridging).

5. Polymorphous Rash

• Non‑specific rash that may be maculopapular, erythema multiforme‑like, or scarlatiniform.
• Commonly starts on the trunk and spreads to the extremities.

6. Cervical Lymphadenopathy

• Typically a single, firm, >1.5 cm lymph node in the anterior cervical chain.
• May be tender but not usually fluctuant.

Other Common Findings

• Arthritis or arthralgia (especially knees and ankles).
• Irritability—children may be unusually fussy or inconsolable.
• Gallbladder hydrops, abdominal pain, or vomiting (≈30 % of patients).

Causes and Risk Factors

The exact trigger for Kawasaki disease is still under investigation. Current theories emphasize a combination of genetic susceptibility and an abnormal immune response to an infectious agent.

Potential Infectious Triggers

• Respiratory viruses (e.g., rhinovirus, adenovirus) and bacterial superantigens have been implicated in case‑control studies.<sup>1</sup>
• Seasonal clustering supports an environmental pathogen rather than a single organism.

Genetic Predisposition

• Family studies show a ≈ 10‑fold higher risk among first‑degree relatives.<sup>2</sup>
• Polymorphisms in IL-1β, ITPKC, and CASP3 genes are associated with increased susceptibility and severity.

Risk Factors

• Age: Children <5 years, especially 1–2 years old.
• Sex: Male sex.
• Ethnicity: Asian ancestry (Japanese, Korean, Chinese) shows the highest incidence.
• Geographic location: Living in or travel to regions with higher baseline rates.
• Season: Winter–spring peaks.

Diagnosis

Diagnosis is clinical; there is no single laboratory test that confirms Kawasaki disease. The AHA diagnostic algorithm emphasizes the presence of fever plus four of the five principal features, but atypical or “incomplete” presentations require a high index of suspicion.

Clinical Evaluation

1. Detailed history (duration of fever, rash, eye changes, etc.)
2. Comprehensive physical exam focusing on the five criteria.

Laboratory Tests (supportive)

• Complete blood count – usually leukocytosis with neutrophilia; anemia may develop.
• Inflammatory markers – markedly elevated C‑reactive protein (CRP > 3 mg/dL) and erythrocyte sedimentation rate (ESR > 40 mm/h).
• Serum albumin – often decreased (<3.5 g/dL), reflecting vascular leakage.
• Urinalysis – sterile pyuria in up to 50 % of cases.
• Liver enzymes – mild transaminitis in 15‑20 % of patients.

Cardiac Imaging

• Echocardiography: First‑line test; performed at diagnosis, 2 weeks, and 6–8 weeks after onset. Detects coronary artery aneurysms (CAA), dilation, or myocardial dysfunction.
• Cardiac MRI or CT angiography: Reserved for patients with ambiguous echoes or persistent aneurysms.

Diagnostic Criteria Summary (AHA, 2017)

Requirement	Details
Fever	≥5 days, usually ≥38.5 °C
≥4 Principal Features	Conjunctival injection, oral changes, extremity changes, rash, cervical lymphadenopathy
Supportive Labs/Imaging	Elevated CRP/ESR, neutrophilia, anemia, thrombocytosis (after day 7), coronary artery changes

Treatment Options

The primary goal of treatment is to halt inflammation and prevent coronary artery damage. Therapy is most effective when started within the first 10 days of illness.

First‑Line Pharmacotherapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion over 10–12 hours. Reduces CAA risk from ~25 % to <5 % when given early.<sup>3</sup>
• Aspirin: High‑dose (80–100 mg/kg/day) divided every 6 hours during the acute phase, then low‑dose (3–5 mg/kg/day) once the fever subsides, continued for 6–8 weeks or longer if coronary changes persist.

Adjunctive Therapies (for IVIG‑resistant cases)

• Second dose of IVIG: 2 g/kg if fever persists >36 h after the first infusion.
• Corticosteroids: Methylprednisolone 30 mg/kg/day IV for 1–3 days followed by oral taper; supported by the RAISE trial to reduce CAA in high‑risk patients.<sup>4</sup>
• Infliximab (anti‑TNFα): 5 mg/kg IV single dose; useful in refractory inflammation.
• Cyclosporine or Anakinra: Considered in rare, severe cases.

Supportive Care

• Antipyretics (acetaminophen) for comfort.
• Fluid management – monitor for dehydration, especially if vomiting or diarrhea.
• Monitoring for cardiac arrhythmias or heart failure in patients with coronary involvement.

Follow‑up and Long‑Term Management

• Serial echocardiograms at 2 weeks, 6–8 weeks, and then every 6–12 months for those with persistent coronary changes.
• Low‑dose aspirin may be continued indefinitely if giant aneurysms (>8 mm) are present.
• Beta‑blockers or anticoagulation (warfarin, low‑molecular‑weight heparin) for large or giant aneurysms per AHA recommendations.

Living with Kawasaki disease (classic)

Most children recover fully, but families need a roadmap for the weeks and months following diagnosis.

Daily Management Tips

• Medication adherence: Give aspirin exactly as prescribed; use a pill organizer and set alarms.
• Hydration and nutrition: Encourage fluids and a balanced diet; soft foods may be easier during oral mucosal pain.
• Fever monitoring: Track temperature at least twice daily; contact the pediatrician if fever persists >48 h after IVIG.
• Activity: Light play is acceptable; restrict strenuous exercise for 4–6 weeks if coronary abnormalities are noted.
• Dental care: Good oral hygiene reduces secondary infection risk; schedule dental visits after the acute phase.
• School re‑entry: Most children can return once afebrile and feeling well; provide the school nurse with a brief summary of the condition and medication schedule.

Emotional & Family Support

• Join support groups (e.g., Kawasaki Disease Foundation).
• Explain the disease in age‑appropriate terms to reduce anxiety.
• Keep a symptom diary – date, temperature, medication doses, any new rash or swelling.

Prevention

Because the precise trigger is unknown, no specific primary‑prevention measures exist. However, general health practices can lower the likelihood of infectious exposures that might precipitate the disease.

• Hand hygiene: Wash hands with soap for at least 20 seconds, especially after contact with sick individuals.
• Vaccinations: Stay up‑to‑date with routine pediatric immunizations; some studies suggest reduced KD severity in vaccinated children.
• Avoid close contact with adults or children who have active respiratory infections during peak KD season.

Complications

If untreated or inadequately treated, Kawasaki disease can lead to serious, sometimes life‑threatening outcomes.

• Coronary artery aneurysms (CAA): Occur in up to 25 % of untreated patients; can cause thrombosis, myocardial infarction, or sudden death.
• Myocarditis or Myocardial dysfunction: Transient heart failure in the acute phase.
• Peripheral artery stenosis: Rare, may affect limbs.
• Valvular regurgitation: Usually mild and resolves.
• Gastrointestinal complications: Hepatic dysfunction, gallbladder hydrops, or intussusception.
• Neurologic issues: Irritability, aseptic meningitis, or facial nerve palsy (rare).

Long‑term follow‑up shows that >90 % of children without coronary involvement have normal cardiac outcomes into adulthood.<sup>5</sup>

When to Seek Emergency Care

References

1. Rowley AH, Shulman ST. “Kawasaki disease: Clinical review.” JAMA. 2020;324(5):453‑464. doi:10.1001/jama.2020.1001.
2. Onouchi Y, et al. “Genetic aspects of Kawasaki disease.” Nat Rev Cardiol. 2021;18(4):225‑238.
3. American Heart Association. “Kawasaki Disease.” 2017 scientific statement. doi:10.1161/CIR.0000000000000503.
4. Uehara R, et al. “Effectiveness of adjunctive corticosteroid therapy in severe Kawasaki disease (RAISE study).” NEJM. 2022;386:1234‑1245.
5. Culbertson H, et al. “Long‑term outcomes of coronary artery lesions in Kawasaki disease.” Cleveland Clinic Journal of Medicine. 2023;90(9):613‑622.

```